Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLURAZEPAM

All products: not a benefit

Other products in the same Health Canada class (N05C, N05CD) — coverage varies; not interchangeable

  • Nitrazepam (Mogadon): general benefit
  • Temazepam (Restoril): general benefit
  • Triazolam (Halcion): general benefit, Not a benefit
  • Midazolam (Versed): limited Use 495, 496, Not a benefit
  • Eszopiclone (Lunesta): not a benefit
  • Zolpidem (Sublinox): not a benefit

1 more in the class list below

Dalmane · DIN 00012696 · 15mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-07-08 — choose a marketed DIN from the same-category list.Discontinued 2016-07-08 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-07-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-07-08 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dalmane · DIN 00012696 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2016-07-08 · brand DALMANE · ATC N05CD01 FLURAZEPAM · form Capsule · route Oral · ingredients FLURAZEPAM HYDROCHLORIDE 15 MG · company Valeant canada lp / valeant canada s.e.c. · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Dalmane: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4697 · Verify on the e-Formulary ↗ (DIN 00012696)

Source record
DIN 00012696: Dalmane Raw flags: notABenefit=Y, sec3=Y Item: 282400016; group id 521; item number 1410; lccId None; manufacturer id VAL Source form: Cap; strength: 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00012696 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4697
Interchangeable products
Flurazepam · DIN 00521698 · $0.1166
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2016-07-08 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FLURAZEPAM (flurazepam hydrochloride) is indicated for the symptomatic relief of transient and short- term insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening. The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning. 1.1 Pediatrics Pediatrics (<15 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLURAZEPAM in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. (see 7.1.3 Pediatrics) 1.2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of FLURAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see Falls and Fractures; 4.1 Dosing Considerations). https://pdf.hres.ca/dpd_pm/00063186.PDF PM date: December 31, 1982 Source product: FLURAZEPAM; DIN 00521698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Dalmane: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026